tetano
Editor, Senior Moderator
Adv Sci (Weinh)
. 2022 Apr 11;e2104333.
doi: 10.1002/advs.202104333. Online ahead of print.
Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma
Ding Yu[SUP] 1 2 [/SUP], Yu-Feng Li[SUP] 3 [/SUP], Hong Liang[SUP] 1 2 [/SUP], Jun-Zheng Wu[SUP] 1 [/SUP], Yong Hu[SUP] 4 [/SUP], Yan Peng[SUP] 4 [/SUP], Tao-Jing Li[SUP] 2 [/SUP], Ji-Feng Hou[SUP] 5 [/SUP], Wei-Jin Huang[SUP] 5 [/SUP], Li-Dong Guan[SUP] 5 [/SUP], Ren Han[SUP] 4 [/SUP], Yan-Tao Xing[SUP] 4 [/SUP], Yong Zhang[SUP] 2 [/SUP], Jia Liu[SUP] 3 [/SUP], Lu Feng[SUP] 4 [/SUP], Chun-Yan Li[SUP] 2 [/SUP], Xiao-Long Liang[SUP] 4 [/SUP], Ya-Ling Ding[SUP] 1 [/SUP], Zhi-Jun Zhou[SUP] 4 [/SUP], De-Ming Ji[SUP] 4 [/SUP], Fei-Fei Wang[SUP] 4 [/SUP], Jian-Hong Yu[SUP] 4 [/SUP], Kun Deng[SUP] 4 [/SUP], Dong-Mei Xia[SUP] 4 [/SUP], De-Mei Dong[SUP] 2 [/SUP], Heng-Rui Hu[SUP] 3 [/SUP], Ya-Jie Liu[SUP] 3 [/SUP], Dao-Xing Fu[SUP] 2 [/SUP], Yan-Lin He[SUP] 2 4 [/SUP], Dong-Bo Zhou[SUP] 2 [/SUP], Hui-Chuan Yang[SUP] 6 [/SUP], Rui Jia[SUP] 6 [/SUP], Chang-Wen Ke[SUP] 7 [/SUP], Tao Du[SUP] 2 [/SUP], Yong Xie[SUP] 2 [/SUP], Rong Zhou[SUP] 2 [/SUP], Ce-Sheng Li[SUP] 4 [/SUP], Man-Li Wang[SUP] 3 [/SUP], Xiao-Ming Yang[SUP] 6 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) remains a global public health threat. Hence, more effective and specific antivirals are urgently needed. Here, COVID-19 hyperimmune globulin (COVID-HIG), a passive immunotherapy, is prepared from the plasma of healthy donors vaccinated with BBIBP-CorV (Sinopharm COVID-19 vaccine). COVID-HIG shows high-affinity binding to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein, the receptor-binding domain (RBD), the N-terminal domain of the S protein, and the nucleocapsid protein; and blocks RBD binding to human angiotensin-converting enzyme 2 (hACE2). Pseudotyped and authentic virus-based assays show that COVID-HIG displays broad-spectrum neutralization effects on a wide variety of SARS-CoV-2 variants, including D614G, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), and Omicron (B.1.1.529) in vitro. However, a significant reduction in the neutralization titer is detected against Beta, Delta, and Omicron variants. Additionally, assessments of the prophylactic and treatment efficacy of COVID-HIG in an Adv5-hACE2-transduced IFNAR[SUP]-/-[/SUP] mouse model of SARS-CoV-2 infection show significantly reduced weight loss, lung viral loads, and lung pathological injury. Moreover, COVID-HIG exhibits neutralization potency similar to that of anti-SARS-CoV-2 hyperimmune globulin from pooled convalescent plasma. Overall, the results demonstrate the potential of COVID-HIG against SARS-CoV-2 infection and provide reference for subsequent clinical trials.
Keywords: COVID-19 hyperimmune globulin; SARS-CoV-2 variant; passive immunotherapy; sinopharm COVID-19 vaccine.
. 2022 Apr 11;e2104333.
doi: 10.1002/advs.202104333. Online ahead of print.
Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma
Ding Yu[SUP] 1 2 [/SUP], Yu-Feng Li[SUP] 3 [/SUP], Hong Liang[SUP] 1 2 [/SUP], Jun-Zheng Wu[SUP] 1 [/SUP], Yong Hu[SUP] 4 [/SUP], Yan Peng[SUP] 4 [/SUP], Tao-Jing Li[SUP] 2 [/SUP], Ji-Feng Hou[SUP] 5 [/SUP], Wei-Jin Huang[SUP] 5 [/SUP], Li-Dong Guan[SUP] 5 [/SUP], Ren Han[SUP] 4 [/SUP], Yan-Tao Xing[SUP] 4 [/SUP], Yong Zhang[SUP] 2 [/SUP], Jia Liu[SUP] 3 [/SUP], Lu Feng[SUP] 4 [/SUP], Chun-Yan Li[SUP] 2 [/SUP], Xiao-Long Liang[SUP] 4 [/SUP], Ya-Ling Ding[SUP] 1 [/SUP], Zhi-Jun Zhou[SUP] 4 [/SUP], De-Ming Ji[SUP] 4 [/SUP], Fei-Fei Wang[SUP] 4 [/SUP], Jian-Hong Yu[SUP] 4 [/SUP], Kun Deng[SUP] 4 [/SUP], Dong-Mei Xia[SUP] 4 [/SUP], De-Mei Dong[SUP] 2 [/SUP], Heng-Rui Hu[SUP] 3 [/SUP], Ya-Jie Liu[SUP] 3 [/SUP], Dao-Xing Fu[SUP] 2 [/SUP], Yan-Lin He[SUP] 2 4 [/SUP], Dong-Bo Zhou[SUP] 2 [/SUP], Hui-Chuan Yang[SUP] 6 [/SUP], Rui Jia[SUP] 6 [/SUP], Chang-Wen Ke[SUP] 7 [/SUP], Tao Du[SUP] 2 [/SUP], Yong Xie[SUP] 2 [/SUP], Rong Zhou[SUP] 2 [/SUP], Ce-Sheng Li[SUP] 4 [/SUP], Man-Li Wang[SUP] 3 [/SUP], Xiao-Ming Yang[SUP] 6 [/SUP]
Affiliations
- PMID: 35403837
- DOI: 10.1002/advs.202104333
Abstract
Coronavirus disease 2019 (COVID-19) remains a global public health threat. Hence, more effective and specific antivirals are urgently needed. Here, COVID-19 hyperimmune globulin (COVID-HIG), a passive immunotherapy, is prepared from the plasma of healthy donors vaccinated with BBIBP-CorV (Sinopharm COVID-19 vaccine). COVID-HIG shows high-affinity binding to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein, the receptor-binding domain (RBD), the N-terminal domain of the S protein, and the nucleocapsid protein; and blocks RBD binding to human angiotensin-converting enzyme 2 (hACE2). Pseudotyped and authentic virus-based assays show that COVID-HIG displays broad-spectrum neutralization effects on a wide variety of SARS-CoV-2 variants, including D614G, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), and Omicron (B.1.1.529) in vitro. However, a significant reduction in the neutralization titer is detected against Beta, Delta, and Omicron variants. Additionally, assessments of the prophylactic and treatment efficacy of COVID-HIG in an Adv5-hACE2-transduced IFNAR[SUP]-/-[/SUP] mouse model of SARS-CoV-2 infection show significantly reduced weight loss, lung viral loads, and lung pathological injury. Moreover, COVID-HIG exhibits neutralization potency similar to that of anti-SARS-CoV-2 hyperimmune globulin from pooled convalescent plasma. Overall, the results demonstrate the potential of COVID-HIG against SARS-CoV-2 infection and provide reference for subsequent clinical trials.
Keywords: COVID-19 hyperimmune globulin; SARS-CoV-2 variant; passive immunotherapy; sinopharm COVID-19 vaccine.